| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/107327480801500105 |
| P698 | PubMed publication ID | 18094659 |
| P2093 | author name string | Pete Anderson | |
| Shaio Woo | |||
| Dolly Aguilera | |||
| Margaret Pearson | |||
| P2860 | cites work | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 |
| Ewing's sarcoma family of tumors: current management | Q28242009 | ||
| Samarium for osteoblastic bone metastases and osteosarcoma | Q28253337 | ||
| Cyclophosphamide cystitis—Identification of acrolein as the causative agent | Q28327805 | ||
| Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature | Q28343882 | ||
| Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites | Q32117273 | ||
| Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life | Q33270398 | ||
| Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. | Q33342842 | ||
| A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors | Q33370363 | ||
| Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas | Q33371392 | ||
| Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas | Q33492994 | ||
| Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial | Q33994512 | ||
| Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma | Q34317458 | ||
| Radiation therapy for control of soft-tissue sarcomas resected with positive margins | Q36774485 | ||
| Pancreatic cancer: an update | Q36790158 | ||
| The role of radiation in retroperitoneal sarcomas: a surgical perspective | Q36838988 | ||
| Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer | Q37219981 | ||
| ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models | Q40138516 | ||
| Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms | Q40245213 | ||
| O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells | Q40331848 | ||
| Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation | Q40390377 | ||
| Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors | Q40550209 | ||
| Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors | Q40590689 | ||
| Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent | Q40899258 | ||
| Gemcitabine and radiosensitization in human tumor cells | Q41260361 | ||
| Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation. | Q42465816 | ||
| Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model | Q42547586 | ||
| Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial | Q43742466 | ||
| Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer | Q44327465 | ||
| Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors | Q44589085 | ||
| Methylene blue reversal of ifosfamide-related encephalopathy | Q44758700 | ||
| Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers | Q44913206 | ||
| Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol | Q45066174 | ||
| Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide | Q45183779 | ||
| Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma | Q45286250 | ||
| The role of preoperative radiotherapy in nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery | Q46528568 | ||
| Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma | Q46735029 | ||
| Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients | Q46781791 | ||
| Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma | Q46827781 | ||
| Metastatic osteosarcoma | Q46850363 | ||
| Preoperative chemotherapy and split-course radiation therapy for patients with localized soft tissue sarcomas: home run, base hit, or strike out? | Q46919081 | ||
| Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. | Q46919092 | ||
| Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases. | Q48561448 | ||
| Preoperative chemoradiation and flap reconstruction provide high local control and low wound complication rates for patients undergoing limb salvage surgery for upper extremity tumors. | Q51079231 | ||
| Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. | Q51770132 | ||
| Chemoradiation for malignant epithelial tumors. | Q52235679 | ||
| Radiotherapy for local control of osteosarcoma. | Q53627639 | ||
| Methylene blue for management of Ifosfamide-induced encephalopathy | Q34481423 | ||
| Ifosfamide in the adjuvant therapy of soft tissue sarcomas. | Q34542947 | ||
| Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. | Q34582869 | ||
| Ifosfamide clinical pharmacokinetics | Q34726639 | ||
| Temozolomide: a novel oral alkylating agent | Q34734267 | ||
| Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity | Q34744670 | ||
| Treatment of Ewing sarcoma family of tumors: current status and outlook for the future | Q35090650 | ||
| Recent advances in systemic therapy of soft tissue sarcomas | Q35117729 | ||
| Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group | Q35558574 | ||
| Pharmacology of Ifosfamide | Q35571717 | ||
| Temozolomide: realizing the promise and potential | Q35587289 | ||
| Role of chemotherapy in patients with soft tissue sarcomas. | Q35728702 | ||
| Gemcitabine-related radiation recall preferentially involves internal tissue and organs | Q35757881 | ||
| Emerging treatments for soft tissue sarcoma of adults | Q35967402 | ||
| Combined modality therapy of gemcitabine and radiation | Q35999708 | ||
| Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas | Q36019305 | ||
| Treatment of metastatic malignant melanoma | Q36115657 | ||
| Evaluating risk factors for the development of ifosfamide encephalopathy | Q36143814 | ||
| Insights into oxazaphosphorine resistance and possible approaches to its circumvention. | Q36254501 | ||
| Advances in chemotherapy for patients with extremity soft tissue sarcoma | Q36323938 | ||
| Biologic basis for combining drugs with radiation | Q36354079 | ||
| Advances in the treatment of primary brain tumors: dawn of a new era? | Q36389892 | ||
| The evolution of chemoradiation for glioblastoma: a modern success story | Q36389897 | ||
| Role of gemcitabine in cancer therapy | Q36429373 | ||
| Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer | Q36443643 | ||
| Systemic chemotherapy in the management of malignant peritoneal mesothelioma. | Q36450227 | ||
| Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention | Q36479560 | ||
| Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art. | Q36503016 | ||
| Overview of gemcitabine activity in advanced breast cancer | Q36517271 | ||
| Reversal of resistance to oxazaphosphorines | Q36569844 | ||
| Improving outcomes in difficult bone cancers using multimodality therapy, including radiation: physician and nursing perspectives | Q36623353 | ||
| Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group | Q36641763 | ||
| Novel therapeutic approaches in pediatric and young adult sarcomas | Q36718644 | ||
| Evidence-based recommendations for local therapy for soft tissue sarcomas | Q36756976 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adaptive radiation therapy | Q180507 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 38-46 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Cancer Control | Q15724614 |
| P1476 | title | Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents | |
| P478 | volume | 15 |
| Q35057029 | Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP. |
| Q34662423 | Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. |
| Q33952091 | Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis |
| Q37025508 | Genistein sensitizes sarcoma cells in vitro and in vivo by enhancing apoptosis and by inhibiting DSB repair pathways |
| Q35945493 | Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments |
| Q28083794 | Osteosarcoma in Korean children and adolescents |
| Q46090646 | Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion |
| Q38683248 | Preoperative radiotherapy for extremity soft tissue sarcoma; past, present and future perspectives on dose fractionation regimens and combined modality strategies. |
| Q39037377 | Repair of radiation damage of U2OS osteosarcoma cells is related to DNA-dependent protein kinase catalytic subunit (DNA-PKcs) activity |
| Q55279406 | Retrospective Analysis of Spectrum of Presentation and Treatment Outcome in Extremity Sarcomas: A Single-Centre Experience. |
| Q34221837 | Sensitization of radio-resistant prostate cancer cells with a unique cytolethal distending toxin |
| Q37885468 | Transport processes of radiopharmaceuticals and -modulators. |
| Q33884881 | WEE1 inhibition sensitizes osteosarcoma to radiotherapy |
| Q33398380 | Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery |
| Q34866445 | [90Y]yttrium microspheres radioembolotherapy in desmoplastic small round cell tumor hepatic metastases |
Search more.